Amgen’s New Cholesterol Drug Wins Approval

Amgen Inc. won U.S. approval for its powerful cholesterol-lowering drug Repatha for certain patients, making it the second in a new class of treatments to come to market.

The Food and Drug Administration limited sales of Repatha to people with hard-to-treat levels of bad cholesterol, according to a statement from the agency. The injection will cost $14,100 a year, Amgen said, and will be available in the U.S. the week of Aug. 31.

Repatha belongs to a category of drugs known as PCSK9 inhibitors designed to help patients with ultra-high bad, or LDL, cholesterol who can’t get their condition under ...